Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
*Staphylococcus aureus* gyrase
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "*Staphylococcus aureus* gyrase" in MCE Product Catalog:
1
Research Areas:
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
Cat. No.: HY-N7066
CAS No.: 91296-86-5
Synonyms: A-56619 hydrochloride
Target:
Research Areas:
Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and *Staphylococcus aureus* infections .
Cat. No.: HY-U00035
CAS No.: 1000277-08-6
Target:
Research Areas:
MGB-BP-3 is an orally aective Gram-positive bactericide and DNA-binding agent. MGB-BP-3 blocks transcription initiation by binding to AT-rich bacterial DNA regions, and interferes with the functions of DNA gyrase and topoisomerase IV, but does not stabilize cleavage complexes or induce the SOS response. MGB-BP-3 induces energy depletion in *Staphylococcus aureus* and inhibits spore formation in *Clostridioides difficile*, exhibiting intrinsic resistance resilience. MGB-BP-3 can be used in the research of *Clostridioides difficile*-associated diseases .
Cat. No.: HY-121272
CAS No.: 98106-17-3
Synonyms: A-56619
Target:
Research Areas:
Difloxacin (A-56619) is an orally active bactericidal agent. Difloxacin inhibits bacterial DNA gyrase. Difloxacin exhibits concentration-dependent bactericidal activity. Difloxacin shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin can be used in research related to colibacillosis and Staphylococcus aureus infections .
Cat. No.: HY-156014
Target:
Research Areas:
qsl-304 is a DNA gyrase B inhibitor. qsl-304 is an antibacterial agent, with an IC50 of 31.23 mg/mL against the Staphylococcus aureus sa-P2003 .
Cat. No.: HY-115990
CAS No.: 2883403-42-5
Target:
Research Areas:
Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
Cat. No.: HY-W264454
CAS No.: 5342-95-0
Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research .
Cat. No.: HY-178949
Target:
Research Areas:
MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
Cat. No.: HY-172264
Target:
Research Areas:
XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with bacterial gyrase. XT17 can be used in the research of the anti - infection field .
Cat. No.: HY-170567
CAS No.: 3087956-87-1
Target:
Research Areas:
DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .
Cat. No.: HY-168511
CAS No.: 2247443-72-5
Target:
Research Areas:
DNA Gyrase-IN-13 (compound 1b) is a DNA Gyrase inhibitor. DNA Gyrase-IN-13 has antibacterial activity. DNA Gyrase-IN-13 has an IC50 value of 1.81 μM for Staphylococcus aureus DNA gyrase .
Cat. No.: HY-149534
Target:
Research Areas:
DNA Gyrase-IN-9 (compound 4j) is an antibacterial agent that targets DNA gyrase. The MIC to inhibit Gram bacteria is 0.5-2 μg/mL, and the MBC to kill Gram bacteria is 2-8 μg/mL. DNA Gyrase-IN-9 inhibits DNA gyrase in Staphylococcus aureus with IC50=6.29 μg/mL .
Cat. No.: HY-147948
CAS No.: 2416400-32-1
Target:
Research Areas:
DNA Gyrase-IN-4 (compound 8p) is a potent DNA gyrase inhibitor, with an IC50 of 0.13 μM. DNA Gyrase-IN-4 shows excellent antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Salmonella and Escherichia coli, with MIC values of 0.05, 0.05, 0.05, and 8 μg/mL, respectively .
Cat. No.: HY-146403
CAS No.: 2408695-41-8
Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
Cat. No.: HY-161788
CAS No.: 2497486-58-3
Target:
Research Areas:
DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC50 is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC50 of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .
Cat. No.: HY-172109
Target:
Research Areas:
DNA Gyrase-IN-15 (Compound 11) is an antimicrobial agent and inhibitor of DHPS and DNA gyrase, with IC50s of 1.73 and 0.07 µM, respectively. DNA Gyrase-IN-15 shows antimicrobial activity against Enterococcus faecalis (MIC of 15.62 µg/mL), Acinetobacter baumannii, Enterobacter species (MIC of 7.81 µg/mL), Pseudomonas aeruginosa, Klebsiella pneumoniae and Staphylococcus aureus. DNA Gyrase-IN-15 also shows antibiofilm activity against Enterococcus faecalis .
Cat. No.: HY-125424
CAS No.: 1417548-17-4
Target:
Research Areas:
AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
Cat. No.: HY-14780
CAS No.: 904302-98-3
Synonyms: NXL 101
Research Areas:
Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
Cat. No.: HY-161937
CAS No.: 2364479-10-5
Target:
Research Areas:
Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC50 is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice .
Cat. No.: HY-163104
CAS No.: 2879255-03-3
Antibacterial agent 169 (Compound 28) is a pyrrolamide-type GyrB/ParE inhibitor with antibacterial activity. Antibacterial agent 169 has an inhibitory effect on Gyrase and Topo IV of Staphylococcus aureus, with IC50 values of 49 nmol/L and 1.513 μmol/L respectively .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
